Reshape Lifesciences Stock In The News

RSLS Stock  USD 0.64  0.03  4.48%   
Our overall analysis of ReShape Lifesciences' news coverage and content from conventional and social sources shows investors' bearish mood towards ReShape Lifesciences. The specific impact of ReShape Lifesciences news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of ReShape Lifesciences' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using ReShape Lifesciences headlines in addition to utilizing other, more conventional financial analysis modules. Check out ReShape Lifesciences Backtesting and ReShape Lifesciences Hype Analysis.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

ReShape Lifesciences Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
https://www.globenewswire.com/news-release/2025/03/10/3039737/0/en/ReShape-Lifesciences-Receives-Notice-of-Allowance-for-U-S-Patent-Related-to-Its-Proprietary-Diabetes-Neuromodulation-Technology.html
 Bullish
Macroaxis News: globenewswire.com
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
https://www.globenewswire.com/news-release/2025/02/25/3032042/0/en/ReShape-Lifesciences-Signs-Distribution-Agreement-in-Canada-With-Liaison-Medical-for-its-Next-Generation-Lap-Band-2-0-FLEX.html
 Neutral
Macroaxis News: globenewswire.com
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
https://www.globenewswire.com/news-release/2025/02/16/3026963/0/en/ReShape-Lifesciences-Announces-Pricing-of-Upsized-6-0-Million-Public-Offering.html
 Neutral
Macroaxis News: globenewswire.com
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
https://www.globenewswire.com/news-release/2025/02/03/3019532/0/en/ReShape-Lifesciences-Granted-Key-International-Patent-in-Israel-for-Its-Proprietary-Diabetes-Neuromodulation-Technology.html
 Bullish
Macroaxis News: globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – RSLS, TURN, RDW, NEUE
https://www.globenewswire.com/news-release/2025/01/24/3015142/0/en/HAREHOLDER-ALERT-The-M-A-Class-Action-Firm-Is-Investigating-the-Merger-RSLS-TURN-RDW-NEUE.html
 Bullish
Macroaxis News: globenewswire.com
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
https://www.globenewswire.com/news-release/2023/11/21/2784030/0/en/ReShape-Lifesciences-Enters-into-Warrant-Exercise-Transaction-for-1-2-Million-in-Gross-Proceeds.html
 Bullish
Macroaxis News: globenewswire.com
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
https://www.globenewswire.com/news-release/2023/11/08/2776710/0/en/ReShape-Lifesciences-Reports-Third-Quarter-Ended-September-30-2023-Financial-Results-and-2024-Cost-Reduction-Plan.html
 Neutral
Macroaxis News: globenewswire.com
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
https://www.globenewswire.com/news-release/2023/11/06/2774128/0/en/ReShape-Lifesciences-to-Announce-Financial-Results-for-the-Third-Quarter-Ended-September-30-2023-and-Provide-Corporate-Update.html
 Neutral
Macroaxis News: globenewswire.com
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
https://www.globenewswire.com/news-release/2023/09/29/2752173/0/en/ReShape-Lifesciences-Announces-Pricing-of-3-0-Million-Public-Offering.html
 Neutral
Macroaxis News: globenewswire.com
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
https://www.globenewswire.com/news-release/2023/09/22/2747973/0/en/ReShape-Lifesciences-Announces-Participation-in-the-LD-Micro-Main-Event-XVI.html
 Neutral

ReShape Lifesciences Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide ReShape and other traded companies coverage with news coverage. We help investors stay connected with ReShape headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on ReShape Stock performance. Please note that trading solely based on the ReShape Lifesciences hype is not for everyone as timely availability and quick action are needed to avoid losses.
ReShape Lifesciences' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help ReShape Lifesciences investors visualize upcoming and past events in order to time the market based on ReShape Lifesciences noise-free hype analysis.
ReShape Lifesciences stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the ReShape earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about ReShape Lifesciences that are available to investors today. That information is available publicly through ReShape media outlets and privately through word of mouth or via ReShape internal channels. However, regardless of the origin, that massive amount of ReShape data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ReShape Lifesciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ReShape Lifesciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ReShape Lifesciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ReShape Lifesciences alpha.

ReShape Largest EPS Surprises

Earnings surprises can significantly impact ReShape Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-14
2024-06-30-0.12-0.060.0650 
2024-05-15
2024-03-31-0.16-0.090.0743 
2024-02-23
2023-12-31-0.18-0.110.0738 
2014-11-12
2014-09-30-1.44-1.20.2416 
2023-11-08
2023-09-30-1.2-0.80.433 
2023-08-07
2023-06-30-1.79-1.080.7139 
View All Earnings Estimates

ReShape Lifesciences Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to ReShape Lifesciences Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Gurufocus Stories at Macroaxis
10th of March 2025
ReShape Lifesciences Receives Notice of Allowance for U.S. Pate
at gurufocus.com 
Google News at Macroaxis
28th of February 2025
RSLS Stock Touches 52-Week Low at 0.99 Amid Market Challenges - Investing.com
at news.google.com 
Google News at Macroaxis
20th of February 2025
ReShape Lifesciences Announces Securities Purchase Agreement - TipRanks
at news.google.com 
seekingalpha News
3rd of February 2025
ReShape Lifesciences receives international patent in Israel shares rise
at seekingalpha.com 
Macroaxis News: globenewswire.com
13th of January 2025
ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset...
at globenewswire.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ReShape Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ReShape Lifesciences' short interest history, or implied volatility extrapolated from ReShape Lifesciences options trading.

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.